Monte Rosa Therapeutics

What Monte Rosa Therapeutics does

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines that selectively eliminate disease-causing proteins by reprogramming the cell's natural ubiquitin-proteasome degradation system. Founded in 2018 and dual-headquartered in Boston, Massachusetts and Basel, Switzerland, the company went public on NASDAQ in June 2021 under the ticker GLUE. Its QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI/ML — including geometric deep learning — with chemistry, biology, automation, proteomics, and structure-based design to rationally design MGDs targeting approximately 85% of proteins considered undruggable by traditional small-molecule approaches.

The pipeline spans three clinical-stage programs and multiple preclinical assets. MRT-2359 is a GSPT1-directed degrader in Phase 1/2 development for metastatic castration-resistant prostate cancer and other MYC-driven cancers, with a planned Phase 2 combination trial using ERLEADA supplied by Johnson & Johnson. MRT-6160 is a VAV1-directed degrader for immune-mediated diseases, globally licensed to Novartis. MRT-8102 is a NEK7-directed degrader targeting IL-1β-driven inflammatory diseases via the NLRP3 inflammasome; Phase 1 data demonstrated 85% CRP reduction and 94% CRP normalization in elevated CVD-risk subjects. Preclinical programs include MRT-55811 (CCNE1-directed, IND planned 2026) and a CDK2-directed program.

Monte Rosa generates revenue through strategic collaborations and licensing agreements with major pharmaceutical partners rather than product sales. Its principal revenue streams include a $150 million upfront from the October 2024 Novartis VAV1 license, a $120 million upfront from a September 2025 Novartis collaboration, and a Roche collaboration potentially worth over $2 billion; the company is also eligible for milestones, tiered royalties, and a 30% US P&L share on co-funded programs. FY2025 collaboration revenue was $123.7 million, up 64% year-over-year. Distribution occurs through clinical trial participation, with commercial distribution expected via pharmaceutical partners.

Name

Monte Rosa Therapeutics

Legal name

Monte Rosa Therapeutics, Inc.

Website

https://monterosatx.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing AI/ML-powered molecular glue degrader medicines to selectively eliminate previously undruggable disease-causing proteins across oncology, immunology, and inflammatory diseases, generating revenue through strategic licensing and collaboration agreements with major pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Molecular glue degraders
• Targeted protein degradation
• Oncology drug discovery
• Immunology drug development
• Biopharmaceutical therapeutics

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Collaboration Revenue: Revenue from strategic partnerships and licensing agreements with pharmaceutical companies including Novartis and Roche. The company received $150 million upfront payment from Novartis for VAV1 license and $120 million upfront from second Novartis collaboration, with potential milestone payments up to $5.7 billion.
2. Co-funding and Profit Sharing: Co-funds Phase 3 clinical development and shares profits/losses associated with manufacturing and commercialization of MRT-6160 in the US (30% US P&L share). Also eligible for tiered royalties on ex-US net sales.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Monte Rosa Therapeutics develops rationally designed molecular glue degrader (MGD) medicines that reprogram the cell's natural protein degradation system to selectively eliminate hard-to-target disease-causing proteins. The company leverages its proprietary QuEEN discovery engine—combining AI/ML, structural biology, proteomics, and chemistry—to advance a clinical pipeline targeting oncology (MRT-2359 for prostate cancer, MRT-55811 for CCNE1-amplified tumors), immunology (MRT-6160, licensed to Novartis), and inflammatory diseases (MRT-8102). It monetizes these assets through strategic collaboration and licensing agreements with major pharmaceutical partners while retaining co-development and profit-sharing rights.

Product overview

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines using its proprietary QuEEN discovery engine. The company's pipeline includes multiple clinical-stage programs: MRT-6160 (VAV1-directed, licensed to Novartis for immunology), MRT-8102 (NEK7-directed for inflammatory diseases), and MRT-2359 (GSPT1-directed for prostate cancer). Preclinical programs include CCNE1-directed and CDK2-directed degraders for various cancers. The QuEEN platform combines AI/ML, high-throughput screening, proteomics, and structure-based design to create selective MGDs that degrade previously undruggable proteins.

Differentiator

Problem solved

Functional benefit

Brands

• QuEEN: Quantitative and Engineered Elimination of Neosubstrates (QuEEN) discovery engine powered by AI/ML for molecular glue degrader drug discovery

Products and services

• MRT-6160 Potent, highly selective, orally bioavailable molecular glue degrader of VAV1 in development for immune-mediated diseases including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, dermatological disorders, systemic lupus erythematosus, and Sjögren's disease; licensed globally to Novartis for development and commercialization.
• MRT-8102 Potent, highly selective, orally bioavailable NEK7-directed molecular glue degrader for the treatment of inflammatory diseases driven by IL-1β and the NLRP3 inflammasome, including cardiovascular disease, gout, osteoarthritis, and neurologic disorders (Parkinson's, Alzheimer's). Phase 1 data showed 85% CRP reduction and 94% CRP normalization in elevated CVD-risk subjects.
• MRT-2359 Potent, highly selective, orally bioavailable GSPT1-directed molecular glue degrader for the treatment of MYC-driven cancers, including metastatic castration-resistant prostate cancer (mCRPC); disrupts translation through selective degradation of GSPT1. Achieved 100% PSA response rate and 100% disease control rate in AR-mutant mCRPC patients; 67% RECIST disease control rate in combination across evaluable patients.
• MRT-55811 (CCNE1-directed Molecular Glue Degrader) Cyclin E1 (CCNE1)-directed molecular glue degrader in preclinical development for the treatment of CCNE1-amplified solid tumors including ovarian, endometrial, gastric, and breast cancers.
• CDK2-directed Molecular Glue Degrader Preclinical program targeting CDK2 for the treatment of HR-positive/HER2-negative breast cancer and other cyclin E1-amplified cancers.

Quantifiable outcome

• MRT-8102 demonstrated 85% CRP reduction and 94% CRP normalization in Phase 1 study
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Five partnerships are on record, tiered minor, flagship and core.

• Johnson & JohnsonminorStrategic or Co-development Partner · 1 March 2026Clinical supply agreement to evaluate MRT-2359 in combination with ERLEADA (apalutamide) for metastatic castration-resistant prostate cancer. Planned Phase 2 trial to assess efficacy and safety in up to 25 patients.
• NovartisflagshipStrategic or Co-development Partner · 1 September 2025Second collaboration to develop novel degraders for immune-mediated diseases leveraging Monte Rosa's QuEEN platform. Received $120 million upfront with potential total payments up to $5.7 billion including milestones and royalties.
• NovartisflagshipStrategic or Co-development Partner · 1 October 2024Global exclusive development and commercialization license agreement to advance VAV1-directed molecular glue degraders including MRT-6160. Monte Rosa received $150 million upfront payment. Eligible for up to $2.1 billion in milestones, co-funds Phase 3, and shares 30% US P&L with tiered ex-US royalties.
• RochecoreStrategic or Co-development Partner · 1 October 2023Strategic collaboration and licensing agreement to discover and develop MGDs against targets in cancer and neurological diseases, leveraging Monte Rosa's QuEEN discovery engine.
• Yeda (Weizmann Institute of Science)minorStrategic or Co-development Partner · 1 January 2022License and research collaboration to accelerate discovery of novel covalent molecular glue degraders.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders using its Pegasus platform. Kymera is a direct competitor to Monte Rosa in the molecular glue degrader space, with overlapping oncology and immunology targets. Both companies compete for pharma partnerships and clinical milestones in protein degradation. <parameter name="source_id">

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MonteRosaTx
• LinkedInlinkedin.com/company/monte-rosa-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monte Rosa Therapeutics